D&A at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TG Therapeutics's D&A?
- TG Therapeutics (TGTX) reported D&A of $32K in Q1 2026.
- How has TG Therapeutics's D&A changed year-over-year?
- TG Therapeutics's D&A increased by 300.0% year-over-year, from $8K to $32K.
- What is the long-term trend for TG Therapeutics's D&A?
- Over 4 years (2021 to 2025), TG Therapeutics's D&A has grown at a -32.4% compound annual growth rate (CAGR), from $282K to $59K.
- What does D&A mean?
- The non-cash accounting expense for the wear and tear or expiration of assets.
- How do you interpret D&A?
- Higher levels suggest a larger asset base, while stability indicates consistent capital expenditure patterns.
- How does D&A compare across companies?
- Standard across all capital-intensive industries; lower for asset-light biotech firms.